Vatiquinone
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Dec 8, 2022 → Dec 31, 2027
NCT ID
NCT05515536About Vatiquinone
Vatiquinone is a phase 3 stage product being developed by PTC Therapeutics for Friedreich Ataxia. The current trial status is active. This product is registered under clinical trial identifier NCT05515536. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 8 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07159139 | Pre-clinical | Active |
| NCT05515536 | Phase 3 | Active |
| NCT05485987 | Phase 2 | Completed |
| NCT05218655 | Phase 3 | Completed |
| NCT04378075 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Friedreich Ataxia